You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Human anti-human antibodies (HAHA)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Isolation of Human Recombinant Therapeutic Monoclonal

Recruiting
  • Pseudomonas Aeruginosa
  • Multi-antibiotic Resistance
  • Isolation of anti-Pseudomonas antibodies from type B lymphocytes
  • Grenoble, France
    Chu Grenoble Alpes
May 6, 2022

Nanoparticle for DSA Removal

Recruiting
  • Kidney Failure
  • Presence of Donor Specific Antibodies
    • Zurich, ZH, Switzerland
      University Hospital Zurich, Division of Anaesthesiology
    Mar 11, 2022

    Colorectal Cancer Trial in Frankfurt, Zurich (Oxaliplatin, 5-Fluorouracil, Leucovorin)

    Completed
    Has Results
    • Colorectal Cancer
    • Frankfurt, Germany
    • +1 more
    Oct 3, 2022

    HIV-1, Human Immunodeficiency Virus 1, Immunodeficiency Virus Type 1, Human Trial (MK-8510)

    Not yet recruiting
    • HIV-1
    • +3 more
    • (no location specified)
    Jan 17, 2023

    Healthy Subjects Trial in Charlottesville (Ultrasound stimulation intensity, Ultrasound stimulation site)

    Recruiting
    • Healthy Subjects
    • Ultrasound stimulation intensity
    • Ultrasound stimulation site
    • Charlottesville, Virginia
      University of Virginia, Division of Nephrology; Center for Immun
    Jan 6, 2023

    COVID-19 Trial in Hong Kong (BRII-196 and BRII-198, Placebo)

    Withdrawn
    • COVID-19
    • BRII-196 and BRII-198
    • Placebo
    • Hong Kong, China
      Investigative Site 1
    Mar 1, 2022

    Standard Operating Procedures for Anti-HPV Antibody Detection in

    Completed
    • Human Papilloma Virus Infection
    • First-void urine collection
    • Blood draw
    • Wilrijk, Antwerp, Belgium
      university of Antwerp - centre for the evaluation of vaccination
    Nov 7, 2022

    HIV Antibodies Trial run by the NIAID (VRC-HIVMAB091-00-AB, EDP)

    Completed
    • HIV Antibodies
    • VRC-HIVMAB091-00-AB
    • EDP
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Oct 8, 2022

    Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, SLE Nephritis Trial (KYV-101, Cyclophosphamide,

    Not yet recruiting
    • Idiopathic Inflammatory Myopathies
    • +3 more
    • (no location specified)
    Nov 21, 2023

    SARS CoV 2 Infection, SARS-CoV-2 Acute Respiratory Disease Trial in Bangkok (Human IgG1 anti-SARS-CoV-2 antibody cocktail,

    Completed
    • SARS CoV 2 Infection
    • SARS-CoV-2 Acute Respiratory Disease
    • Human IgG1 anti-SARS-CoV-2 antibody cocktail
    • Placebo
    • Bangkok, Thailand
      National Cancer Institute of Thailand
    Jul 5, 2022

    Head and Neck Carcinoma, Adult Disease Trial in Villejuif (HPVDC injection level dose 1, injection level dose 1, HPVDC

    Recruiting
    • Head and Neck Carcinoma
    • Adult Disease
    • HPVDC injection level dose 1
    • +3 more
    • Villejuif, France
      Gustave Roussy
    Aug 17, 2023

    Community-acquired Pneumonia, Bacterial Pneumonia Trial in Cincinnati (CMTX-101, Placebo)

    Recruiting
    • Community-acquired Pneumonia
    • Bacterial Pneumonia
    • Cincinnati, Ohio
      Medpace Clinical Pharmacology Unit
    Jan 20, 2023

    COVID-19 Trial in Beijing (BRII-196 and BRII-198, Placebo)

    Completed
    • COVID-19
    • BRII-196 and BRII-198
    • Placebo
    • Beijing, Beijing, China
      Investigative Site
    Mar 1, 2022

    Tetanus Trial in China (TNM002 (low dose), TNM002 (medium dose), TNM002 (high dose))

    Completed
    • Tetanus
    • TNM002 (low dose)
    • +4 more
    • Shantou, Guangdong, China
    • +3 more
    Nov 20, 2022

    Healthy Trial in Qingdao (VDJ001, Placebo)

    Completed
    • Healthy
    • Qingdao, Shandong, China
      the Affliated Hospital of Qingdao University
    Aug 30, 2023

    Ovarian Cancer Trial in New York (90Y-hu3S193, 111In-hu3S193)

    Completed
    Has Results
    • Ovarian Cancer
    • 90Y-hu3S193
    • 111In-hu3S193
    • New York, New York
      Memorial Sloan-Kettering Cancer Center
    Oct 3, 2022

    HIV Trial (gp160 MN/LAI-2, Aluminum hydroxide)

    Completed
    • HIV Infections
    • gp160 MN/LAI-2
    • Aluminum hydroxide
    • (no location specified)
    Oct 13, 2021

    Osteonecrosis Due to Drugs, Jaw Trial in Besançon (Human Amniotic Membrane, Conventional/Standard treatment)

    Active, not recruiting
    • Osteonecrosis Due to Drugs, Jaw
    • Human Amniotic Membrane
    • Conventional/Standard treatment
    • Besançon, France
      CHU de Besancon
    Dec 21, 2022

    Multiple Myeloma Trial in Shanghai (Human Derived anti-BCMA CAR-T Injection)

    Recruiting
    • Multiple Myeloma
    • Human Derived anti-BCMA CAR-T Injection
    • Shanghai, Shanghai, China
      Shanghai Changzheng Hospital
    Mar 27, 2022

    Metastatic Carcinoma in the Liver, Resectable Mass, Stage IV Colorectal Cancer AJCC v7 Trial in Houston (biological, other,

    Completed
    • Metastatic Carcinoma in the Liver
    • +4 more
    • Durvalumab
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jan 30, 2023

    Malaria Trial in Baltimore (MAM01, Placebo)

    Not yet recruiting
    • Malaria
    • MAM01
    • Placebo
    • Baltimore, Maryland
      Center for Vaccine Development and Global Health, 685 W. Baltimo
    May 26, 2023

    COVID-19; Isolation of Neutralizing Antibodies for Therapeutics

    Active, not recruiting
    • SARS-CoV 2
    • Blood sampling
    • Grenoble, France
      UniversityGrenobleHospital
    Mar 24, 2022

    Chronic Kidney Disease (CKD) Trial in New Haven, New York, Philadelphia (REGN5459, REGN5458)

    Not yet recruiting
    • Chronic Kidney Disease (CKD)
    • New York, New York
      New York University Langone Health - Transplant Institute
    Jul 11, 2022

    Advanced Solid Tumors, Metastatic Solid Tumors Trial (JSKN003)

    Not yet recruiting
    • Advanced Solid Tumors
    • Metastatic Solid Tumors
    • (no location specified)
    Aug 10, 2022

    Communicable Disease Transmission, Zoonotic Disease, Rabies Human Trial in Changchun City (recombinant anti-rabies human mAb

    Completed
    • Communicable Disease Transmission
    • +4 more
    • recombinant anti-rabies human monoclonal antibody injection (SYN023)
    • Rabies Vaccine
    • Changchun City, Jilin, China
      Jilin University
    Sep 23, 2021